The newly issued patent protects Nexalin’s dynamic frequency stimulation method through 2042, reinforcing its strategy for noninvasive, in-home treatment of insomnia, anxiety, and depression.
Key takeaways:
- US Patent 12,629,519 covers transcranial alternating current dynamic frequency stimulation methods for anxiety, depression, and insomnia.
- The patent provides intellectual property protection for Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) platform through 2042.
- The proprietary treatment is designed for in-home use with physician oversight via the Nexalin NeuroCare virtual clinic.
The US Patent and Trademark Office has issued a new patent to Nexalin Technology Inc for its non-invasive, frequency-based deep-brain neurostimulation method designed to treat insomnia, anxiety, and depression.
US Patent 12,629,519, titled “Transcranial Alternating Current Dynamic Frequency Stimulation Method for Anxiety, Depression and Insomnia,” is expected to provide intellectual property protection for Nexalin’s core dynamic frequency stimulation method through 2042.
The patent protects elements of the company’s proprietary Deep Intracranial Frequency Stimulation (DIFS) platform. According to Nexalin, the DIFS technology is designed to deliver advanced frequency-based stimulation waveforms that penetrate deeper regions of the brain than traditional surface-level stimulators. The treatment is intended to be administered and monitored through the Nexalin NeuroCare virtual clinic, a model for physician-supervised, drug-free, noninvasive mental health and sleep treatment for in-home use.
“This patent represents another major milestone for Nexalin and strengthens the defensibility of our long-term platform strategy,” says Mark White, CEO of Nexalin Technology, in a release. “Although anxiety, depression and insomnia are among the most widespread and difficult-to-treat conditions in mental health, they are only the beginning for the Nexalin NeuroCare in-home clinic model. We believe our DIFS technology has the potential to create an entirely new category of non-invasive, deep-brain, drug-free treatment for patients who need alternatives beyond traditional medications and clinic-based treatment models.”
Nexalin is currently advancing its next-generation HALO Clarity platform alongside the virtual clinic ecosystem. The strategy combines proprietary neurostimulation hardware with artificial intelligence-enabled remote patient monitoring, treatment-compliance data capture, clinical workflow tools, and physician oversight.
“We believe the future of neurostimulation will be defined by three things: clinically meaningful technology, protected intellectual property and scalable care delivery,” says White in a release. “This patent strengthens all three. It protects an important method of dynamic frequency stimulation while supporting our broader mission to make advanced brain-based treatment more accessible to patients through non-invasive, connected and physician-supervised care.”
The patent builds on Nexalin’s broader intellectual property strategy covering applications of its DIFS technology across multiple indications, including Alzheimer’s disease, traumatic brain injury, and post-traumatic stress disorder. The company’s Gen-2 15-milliamp neurostimulation device is currently approved in China, Brazil, Oman, and Israel.
More in Insomnia:
ID 437560425| Patent© Onyxprj| Dreamstime.com
